MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is developing an AI-powered voice analysis platform designed to detect drug and alcohol impairment from short speech samples, offering a non-invasive alternative to traditional testing methods. The platform, trained on more than 50 million data points, analyzes over 140 acoustic markers to deliver real-time impairment assessments through Edge AI kiosks, according to a press release.
The company plans initial field testing in 2026, with an initial commercial focus on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges. The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to market research cited by MindBio.
MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers and healthcare, leveraging its proprietary research to address increasing demand for faster, scalable workplace impairment detection. The technology aims to provide rapid results without the need for breathalyzers, saliva tests, urine analysis or laboratory-based testing.
The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for detection in various environments. For more information, visit the company’s newsroom at https://ibn.fm/MBQIF.
MindBio Therapeutics Corp. is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with accuracy, just by using the human voice. The full article is available at https://ibn.fm/Gw5Fa.
